aTyr Pharma Company Profile (NASDAQ:LIFE)

About aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma logoaTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LIFE
  • CUSIP: 53217V10
  • Web: www.atyrpharma.com
Capitalization:
  • Market Cap: $78.56 million
  • Outstanding Shares: 23,806,000
Average Prices:
  • 50 Day Moving Avg: $3.23
  • 200 Day Moving Avg: $3.18
  • 52 Week Range: $2.10 - $4.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.43
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.13 per share
  • Price / Book: 1.55
Profitability:
  • EBIDTA: ($54,140,000.00)
  • Return on Equity: -65.72%
  • Return on Assets: -57.31%
Debt:
  • Current Ratio: 6.17%
  • Quick Ratio: 6.17%
Misc:
  • Average Volume: 121,217 shs.
  • Beta: 3.52
  • Short Ratio: 1.93
 

Frequently Asked Questions for aTyr Pharma (NASDAQ:LIFE)

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How were aTyr Pharma's earnings last quarter?

aTyr Pharma Inc (NASDAQ:LIFE) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.06. View aTyr Pharma's Earnings History.

Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?

3 brokerages have issued 12-month price objectives for aTyr Pharma's shares. Their forecasts range from $2.85 to $4.00. On average, they anticipate aTyr Pharma's share price to reach $3.62 in the next twelve months. View Analyst Ratings for aTyr Pharma.

Who are some of aTyr Pharma's key competitors?

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an IPO on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Who owns aTyr Pharma stock?

aTyr Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), EcoR1 Capital LLC (9.65%), Polaris Venture Management Co. V L.L.C. (7.70%), Vanguard Group Inc. (1.83%), Geode Capital Management LLC (0.47%) and Dimensional Fund Advisors LP (0.24%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.

Who sold aTyr Pharma stock? Who is selling aTyr Pharma stock?

aTyr Pharma's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for aTyr Pharma.

Who bought aTyr Pharma stock? Who is buying aTyr Pharma stock?

aTyr Pharma's stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Renaissance Technologies LLC and Geode Capital Management LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.

How do I buy aTyr Pharma stock?

Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of aTyr Pharma stock cost?

One share of aTyr Pharma stock can currently be purchased for approximately $3.30.

Analyst Ratings

Consensus Ratings for aTyr Pharma (NASDAQ:LIFE) (?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $3.62 (9.60% upside)

Analysts' Ratings History for aTyr Pharma (NASDAQ:LIFE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017BMO Capital MarketsReiterated RatingHoldLowView Rating Details
3/20/2017Citigroup IncBoost Price TargetNeutral$3.00 -> $4.00MediumView Rating Details
3/18/2017JPMorgan Chase & Co.Reiterated RatingHoldMediumView Rating Details
3/31/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for aTyr Pharma (NASDAQ:LIFE)
Earnings by Quarter for aTyr Pharma (NASDAQ:LIFE)
Earnings History by Quarter for aTyr Pharma (NASDAQ:LIFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.50)($0.56)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.67)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.71)($0.65)ViewN/AView Earnings Details
5/11/2016Q1($0.70)($0.68)ViewN/AView Earnings Details
3/30/2016Q4($0.52)($0.70)ViewN/AView Earnings Details
11/10/2015Q3($0.48)($0.48)ViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.74)ViewN/AView Earnings Details
6/18/2015Q115($0.41)($0.38)ViewN/AView Earnings Details
11/5/2013Q313$0.97$1.02$926.10 million$936.00 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.96$0.72$952.06 million$944.00 millionViewN/AView Earnings Details
5/2/2013Q1 2013$1.04$1.07$958.56 million$963.00 millionViewN/AView Earnings Details
2/4/2013Q4 2012$1.11$1.11$988.85 million$998.90 millionViewN/AView Earnings Details
11/1/2012Q312$0.89$0.92$907.91 million$911.00 millionViewN/AView Earnings Details
7/31/2012$0.97$0.96ViewN/AView Earnings Details
2/7/2012$1.04$1.06ViewN/AView Earnings Details
10/25/2011$0.88$0.94ViewN/AView Earnings Details
7/28/2011$0.95$0.89ViewN/AView Earnings Details
4/26/2011$0.85$0.85ViewN/AView Earnings Details
2/3/2011$0.87$0.90ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)
2017 EPS Consensus Estimate: ($2.17)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.55)($0.55)($0.55)
Q4 20171($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for aTyr Pharma (NASDAQ:LIFE)
Insider Ownership Percentage: 28.90%
Institutional Ownership Percentage: 44.84%
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)
Institutional Ownership by Quarter for aTyr Pharma (NASDAQ:LIFE)
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/24/2017John MendleinCEOBuy124$3.00$372.00View SEC Filing  
4/20/2017John MendleinCEOBuy2,552$3.00$7,656.00View SEC Filing  
12/21/2016Paul SchimmelDirectorBuy25,000$2.28$57,000.00View SEC Filing  
12/20/2016Ashraf AmanullahVPBuy11,000$2.25$24,750.00View SEC Filing  
12/19/2016John MendleinCEOBuy69,000$2.20$151,800.00View SEC Filing  
12/16/2016Paul SchimmelDirectorBuy50,000$2.48$124,000.00View SEC Filing  
5/11/2016Grove MatsuokaInsiderBuy12,412$3.04$37,732.48View SEC Filing  
4/14/2016Paul SchimmelDirectorBuy66,219$4.18$276,795.42View SEC Filing  
4/13/2016Paul SchimmelDirectorBuy9,835$3.85$37,864.75View SEC Filing  
4/12/2016Paul SchimmelDirectorBuy9,127$3.71$33,861.17View SEC Filing  
4/11/2016Paul SchimmelDirectorBuy32,659$3.57$116,592.63View SEC Filing  
4/8/2016Paul SchimmelDirectorBuy85,000$3.22$273,700.00View SEC Filing  
4/7/2016Paul SchimmelDirectorBuy40,000$3.19$127,600.00View SEC Filing  
4/6/2016Paul SchimmelDirectorBuy25,000$3.20$80,000.00View SEC Filing  
4/5/2016John MendleinCEOBuy2,500$3.55$8,875.00View SEC Filing  
4/5/2016Paul SchimmelDirectorBuy25,000$3.52$88,000.00View SEC Filing  
5/12/2015James E FlynnInsiderBuy50,000$14.00$700,000.00View SEC Filing  
5/12/2015Sofinnova Venture Partners Ix,Major ShareholderBuy320,000$14.00$4,480,000.00View SEC Filing  
5/29/2013David C UprichardDirectorSell2,010$74.04$148,820.40View SEC Filing  
5/28/2013John A CottinghamInsiderSell60,000$74.03$4,441,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for aTyr Pharma (NASDAQ:LIFE)
Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
Source:
DateHeadline
americanbankingnews.com logoaTyr Pharma Inc (LIFE) Receives "Hold" Rating from BMO Capital Markets
www.americanbankingnews.com - May 24 at 11:32 AM
finance.yahoo.com logoaTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
finance.yahoo.com - May 15 at 10:38 AM
americanbankingnews.com logoaTyr Pharma Inc (LIFE) Posts Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - May 12 at 11:48 AM
News IconUPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln deal
www.businessinsider.com - May 11 at 11:47 PM
cnbc.com logoContract medical research firm INC to buy inVentiv in $4.6 billion deal
www.cnbc.com - May 11 at 11:47 PM
finance.yahoo.com logoaTyr Pharma Announces First Quarter 2017 Operating Results
finance.yahoo.com - May 11 at 6:46 PM
finance.yahoo.com logoAtyr Pharma reports 1Q loss
finance.yahoo.com - May 11 at 6:46 PM
americanbankingnews.com logo-$0.55 Earnings Per Share Expected for aTyr Pharma Inc (LIFE) This Quarter
www.americanbankingnews.com - May 10 at 12:10 AM
americanbankingnews.com logoaTyr Pharma Inc (LIFE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:18 AM
americanbankingnews.com logoaTyr Pharma (LIFE) Earns Daily News Impact Rating of -0.10
www.americanbankingnews.com - April 28 at 2:44 PM
streetinsider.com logoaTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 Trial
www.streetinsider.com - April 24 at 7:23 PM
americanbankingnews.com logoaTyr Pharma (LIFE) Earns News Impact Score of -0.12
www.americanbankingnews.com - April 23 at 3:13 PM
americanbankingnews.com logoaTyr Pharma (LIFE) Given Coverage Optimism Rating of -0.06
www.americanbankingnews.com - April 20 at 3:47 PM
americanbankingnews.com logoZacks: Analysts Expect aTyr Pharma Inc (LIFE) to Post -$0.55 Earnings Per Share
www.americanbankingnews.com - April 19 at 7:56 AM
americanbankingnews.com logoaTyr Pharma (LIFE) Getting Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 14 at 1:08 PM
finance.yahoo.com logoaTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
finance.yahoo.com - April 10 at 5:55 PM
americanbankingnews.com logoShort Interest in aTyr Pharma Inc (LIFE) Drops By 9.3%
www.americanbankingnews.com - April 10 at 3:46 PM
finance.yahoo.com logoaTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors - Yahoo Finance
finance.yahoo.com - April 4 at 8:02 AM
biz.yahoo.com logoATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 4 at 8:02 AM
finance.yahoo.com logoaTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference
finance.yahoo.com - March 29 at 10:10 AM
americanbankingnews.com logoaTyr Pharma Inc (LIFE) Price Target Raised to $4.00 at Citigroup Inc
www.americanbankingnews.com - March 24 at 11:31 AM
finance.yahoo.com logoATYR PHARMA INC Financials
finance.yahoo.com - March 22 at 6:26 PM
americanbankingnews.com logoaTyr Pharma Inc (LIFE) Given New $4.00 Price Target at Citigroup Inc
www.americanbankingnews.com - March 20 at 12:32 PM
americanbankingnews.com logoaTyr Pharma Inc (LIFE) Given a $4.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - March 19 at 9:13 PM
bizjournals.com logoaTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results
www.bizjournals.com - March 16 at 7:04 PM
biz.yahoo.com logoATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 7:04 PM
finance.yahoo.com logoaTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases
finance.yahoo.com - March 15 at 6:31 PM
baystreet.ca logoaTyr Pharma (LIFE) Gains on Orphan Drug Designation
www.baystreet.ca - March 3 at 11:14 PM
us.rd.yahoo.com logoaTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
us.rd.yahoo.com - March 3 at 6:13 PM
us.rd.yahoo.com logo8:01 am aTyr Pharma announces that the European Medicines Agency has granted orphan drug designation to Resolaris for the treatment of limb girdle muscular dystrophy patients
us.rd.yahoo.com - March 3 at 6:13 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Target, Frontier, aTyr Pharma, Intelsat - Nasdaq
www.nasdaq.com - March 2 at 10:18 AM
streetinsider.com logoaTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris - StreetInsider.com
www.streetinsider.com - March 2 at 10:18 AM
investopedia.com logoaTyr Pharma Rises 16% on Orphan Drug Status (LIFE)
www.investopedia.com - March 1 at 5:58 PM
investopedia.com logoaTyr Pharma Rises 16% on Orphan Drug Status
www.investopedia.com - March 1 at 5:58 PM
finance.yahoo.com logoaTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 1 at 11:17 AM
baystreet.ca logoaTyr Pharma (LIFE) Spikes on FDA Nod
www.baystreet.ca - February 28 at 6:24 PM
streetinsider.com logoaTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris
www.streetinsider.com - February 28 at 6:24 PM
finance.yahoo.com logo8:01 am aTyr Pharma confirms that its product candidate Resolaris was granted Orphan Drug Designation by the FDA for the treatment of limb girdle muscular dystrophy patients
finance.yahoo.com - February 28 at 6:24 PM
finance.yahoo.com logoaTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
finance.yahoo.com - February 28 at 9:46 AM
finance.yahoo.com logoHigh court ruling limits international reach of patent laws
finance.yahoo.com - February 22 at 6:26 PM
investopedia.com logoAtyr Pharma Spikes 33% on FDA Update (LIFE)
www.investopedia.com - January 20 at 1:06 AM
investopedia.com logoAtyr Pharma Stock Spikes 33% on FDA Updates
www.investopedia.com - January 19 at 8:04 PM
streetinsider.com logoaTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status - StreetInsider.com
www.streetinsider.com - January 19 at 4:52 AM
finanznachrichten.de logoGainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC...
www.finanznachrichten.de - January 18 at 11:50 PM
streetinsider.com logoaTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status
www.streetinsider.com - January 18 at 6:49 PM
us.rd.yahoo.com logoFDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
us.rd.yahoo.com - January 18 at 6:49 PM
finance.yahoo.com logoAtyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares
finance.yahoo.com - December 21 at 7:06 PM

Social

Chart

aTyr Pharma (LIFE) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff